The Israeli Academy of Sciences and Humanities elects antivaxer Yehuda Shoenfeld to its ranks

Academic honors are usually the quiet part of sciencethe handshake, the framed certificate, the polite applause, the
“we’re thrilled to announce…” email that lives forever in a university newsroom. But every so often, an election to a
prestigious academy turns into something far louder: a public argument about credibility, responsibility, and whether
celebrating a scientist’s body of work can be separated from the scientist’s loudest (and most controversial) claims.

That’s the tension surrounding immunologist Yehuda Shoenfeld, elected in 2019 to the
Israel Academy of Sciences and Humanitiesa top-tier recognition in Israeli academic life. The moment
was also a spark: critics who describe Shoenfeld as a vaccine “skeptic” or “antivaxxer” argued the honor risked
elevating ideas they believe fuel vaccine hesitancy. Supporters countered that scientific careers are complex, and that
membership recognizes contributions to immunology and autoimmunity, not a lifetime pledge to every claim a member has
ever made.

If this sounds like the plot of a campus drama, welcome to academiawhere the group chat is peer-reviewed and the
subtweets have footnotes.

What happened: the election, the reaction, and why it mattered

The Israel Academy lists Shoenfeld as elected in 2019, in the Natural Sciences
division, with an academic field of Medicine and affiliation with Reichman University
and Sheba Medical Center. That’s the formal partthe institutional record, the clean line in a CV.

The informal part came from outside the Academy: commentators and some physicians raised alarms that Shoenfeld’s work
and public messaging around vaccines and immune “adjuvants” (ingredients used to boost immune response) have been used
by anti-vaccine movements. They worried that Academy membership could function as a megaphoneturning “member of a
national academy” into a rhetorical shield in future public debates.

The core question isn’t only “Should he have been elected?” It’s also “What does election mean in an age where
scientific prestige travels faster than scientific nuance?”

Who is Yehuda Shoenfeld? A quick (and relevant) profile

Shoenfeld is known for extensive work in autoimmunityhow and why the immune system can mistakenly
attack the body. Autoimmune diseases are medically serious, scientifically complex, and emotionally exhausting for
patients. Researchers who help clarify mechanisms or improve diagnosis and treatment can have an enormous impact.

But Shoenfeld is also closely associated with a controversial concept often called
ASIA: Autoimmune/Inflammatory Syndrome Induced by Adjuvants (sometimes nicknamed
“Shoenfeld’s syndrome”). The idea, proposed in 2011 and developed in later publications, attempts to group a wide range
of symptoms and conditionsoften involving fatigue, pain, and cognitive complaintsunder a single umbrella, triggered
by “adjuvants” or other immune-stimulating exposures.

This is where the story splits into two competing narratives: one argues ASIA brings attention to under-recognized
immune reactions in susceptible people; the other argues ASIA is too broad, too vague, and too easily weaponized into
“vaccines are dangerous” messaging.

The controversy in plain English: “vaccine safety questions” vs “anti-vaccine claims”

Vaccine safety research is real, necessary, and ongoing. Vaccines are medical interventions given to healthy people,
including children, so the bar for safety isand should behigh. Public health agencies continuously monitor adverse
events, update recommendations, and refine formulations.

“Anti-vaccine,” by contrast, is usually used for claims that broadly reject vaccines, exaggerate risks while minimizing
benefits, or use weak evidence (or conspiracy logic) to argue routine immunization is harmful at a population level.

Shoenfeld’s critics place him closer to the second bucket, largely because ASIA-related messaging has focused heavily on
adjuvantsespecially aluminum saltsand because some high-profile papers linked to this research orbit
have been criticized or withdrawn. Supporters often respond that he is not “against vaccines,” and that focusing on
potential rare harms is compatible with supporting immunization overall.

The practical reality is that the internet doesn’t handle “both/and” very well. A nuanced position can be flattened
into a meme in under six minutesfive if someone adds a dramatic soundtrack.

ASIA syndrome: what proponents say

The ASIA framework proposes that in some genetically susceptible individuals, exposure to certain immune-stimulating
substances could trigger a set of symptoms or autoimmune phenomena. In the ASIA literature, “adjuvants” can include
aluminum salts used in some vaccines, but also silicone breast implants, polypropylene meshes, and other exposures.

Proponents argue ASIA provides clinicians with a lens to recognize patternsespecially when patients report symptoms
beginning after a specific exposure and improving when that exposure is removed (for example, after implant removal in
some cases). More recent reviews continue to discuss ASIA in the context of implants and, more controversially, certain
vaccines.

If you’ve ever felt dismissed in a doctor’s office, you can see why an umbrella diagnosis might feel validating: it
says, “Your symptoms are not imaginary.” That emotional dynamic mattersbecause it’s also why broad syndromes can be
medically tempting and socially sticky.

ASIA syndrome: what critics say (and why it’s a big deal)

Many immunologists and allergy specialists argue that ASIA’s diagnostic criteria are too non-specific. Fatigue, pain,
brain fog, and sleep problems are real symptomsbut they also overlap with dozens of conditions (and with life itself
during a stressful decade). When criteria are broad, the risk of mislabeling is high: you can “diagnose” the syndrome
without proving cause.

A notable critique in the allergy/immunology literature argues that available human data do not support the claim that
aluminum-containing vaccine adjuvants cause ASIA, and points out that people receiving allergen immunotherapy may be
exposed to much larger cumulative amounts of injected aluminum than typical vaccine recipientswithout showing higher
autoimmune disease rates in large studies.

This isn’t a minor academic quibble. When a contested syndrome becomes a talking point in vaccine debates, it can shift
public perception from “rare side effects exist” (true) to “vaccines are broadly unsafe” (not supported by high-quality
evidence).

Adjuvants 101: what they are, and why aluminum shows up in the debate

Adjuvants are ingredients added to some vaccines to strengthen the immune response. In everyday terms:
they help the body learn the lesson with fewer “flashcards.” That can mean a smaller amount of antigen, fewer doses, or
more durable protection.

Aluminum salts are among the most widely used adjuvants, with decades of use. The amount of aluminum in
vaccines is smalland aluminum is also common in the environment and diet. For example, infants receive aluminum through
breast milk and formula, and exposure continues through food and water. Vaccine-focused resources often emphasize that
cumulative aluminum exposure from routine vaccines in early infancy is far lower than dietary exposure over the same
period.

None of this means “zero risk.” It means the evidence base supporting routine immunization is large, and the safety
conversation should reflect dose, context, and quality of datanot just a scary-sounding ingredient name.

The paper that fueled the fire: HPV vaccine, mice, and a withdrawal

One reason Shoenfeld’s name repeatedly appears in vaccine debates is association with a cluster of papers claiming
neurological or behavioral effects after exposure to aluminum adjuvants or the HPV vaccine.

In a prominent example, a paper about behavioral abnormalities in young female mice after aluminum adjuvants and the HPV
vaccine Gardasil was withdrawn by the journal Vaccine, citing serious concerns about
scientific soundness. The withdrawal notice stated that outside evaluation found the methodology seriously flawed and
the claims unjustified. Reporting later noted versions of this work or similar claims appeared again in other venues,
sparking criticism about editorial standards and the recycling of contested conclusions.

For critics, this episode is Exhibit A: not merely “asking questions,” but publishing claims with weak methods that can
predictably be amplified by anti-vaccine networks. For defenders, it can be framed as a messy but not unheard-of part of
scientific disputewhere work is challenged, revised, and debated (though withdrawal for flawed methodology is not a
routine badge of honor).

So why would an academy elect a controversial figure?

Academies typically elect members for lifetime achievement, disciplinary impact, and scientific stature. They are not
usually designed as morality tribunalsor as real-time misinformation task forces. In the best-case scenario, election
recognizes foundational contributions while the institution maintains clear standards about evidence and public health.

In the worst-case scenario, election looks like an endorsement of a public narrative the academy never intended to
promote.

There’s also a human factor: committees are composed of experts who may weigh different things. One member prioritizes
citation impact and institution-building. Another prioritizes public trust. A third wonders if controversy today will
look different in ten years. And someone, somewhere, is definitely thinking: “Please, not another headline.”

Prestige can be repurposed

The internet has a trick: it turns “recognized for contributions to autoimmunity research” into “officially validated on
vaccines.” That leap is logically incorrectbut rhetorically powerful. And in health communication, rhetoric can shape
real decisions, including whether parents vaccinate their kids.

Institutions now operate inside a “trust economy”

Scientific institutions do not control how their symbols are used. But they are responsible for anticipating misuse.
That’s why controversy over a single election can matter far beyond one individualit becomes a proxy battle over how
science protects its credibility in public.

What’s the responsible middle ground?

You don’t have to choose between “Shoenfeld is a hero” and “Shoenfeld is a villain.” A more realistic framing looks like
this:

• Autoimmunity research matters, and contributions can be substantial even if some claims are disputed.
• Vaccine safety is a legitimate field, but it must rest on robust methods and reproducible evidence.
• Broad syndromes with non-specific criteria can become magnets for over-attribution and fear-based narratives.
• Institutions should communicate clearly about what honors meanand what they do not mean.

If an academy elects someone whose work is used in vaccine controversy, transparency becomes part of the job. Not a
press-release paragraph. A real explanation: what the election recognizes, what standards of evidence the institution
affirms, and how it distinguishes scientific debate from public-health misinformation.

How readers can evaluate claims in this space (without becoming an immunologist)

1) Follow the weight of evidence, not the volume of confidence

A confident claim in a viral post is not the same as a conclusion supported by multiple high-quality studies. Look for
large epidemiological work, replicated findings, and consensus statements that cite bodies of evidencenot just one
paper.

2) Watch for “syndrome creep”

If a condition’s triggers expand to include many unrelated exposures and its symptoms overlap with everything from
fatigue to cognitive issues, specificity may be low. Low specificity makes causation easy to assert and hard to prove.

3) Distinguish “possible” from “probable”

In biology, many things are possible. The question is whether the best evidence shows a causal relationship that’s
probable and meaningful at population scale.

4) Treat ingredient fear like a math problem

Dose matters. Route of exposure matters. Timing matters. “Contains aluminum” is not a conclusion; it’s the start of a
conversation.

What this election symbolizes in 2026: science, status, and the public square

The Shoenfeld election controversy is ultimately about more than one immunologist or one academy vote. It’s about the
modern reality that scientific status has become a public assetand sometimes a public weapon.

When an institution grants prestige, it’s not just honoring a career. It’s also generating a shortcut in the minds of
non-experts: “This person is trustworthy.” Most of the time, that shortcut is useful. Sometimes, it gets exploited.

That’s why these debates keep recurringaround vaccines, climate, nutrition, and other high-stakes topics. The world
doesn’t just need more information. It needs reliable signals about what information deserves trust.

Experiences from the front lines: what controversies like this feel like (and what they teach)

To understand why an academy election can trigger outsized backlash, it helps to look at the human experiences that sit
behind the headlinesespecially in medicine and public health, where trust is not an abstract concept. It’s the thing
that determines whether a parent shows up for an appointment, whether a patient completes treatment, and whether a
community accepts lifesaving prevention.

The clinician experience: “I’m not arguing with youI’m trying to keep you safe.”

Many pediatricians and family doctors describe a familiar pattern: a patient arrives with a stack of screenshots, a
handful of scientific-sounding phrases, and a deep fear that something “is being hidden.” The clinician isn’t just
answering a question about vaccines; they’re responding to a story the patient has already internalized.

In that moment, academic prestige can cut both ways. If a controversial figure holds a prestigious title, it can feel
like “proof” to the anxious patient that mainstream medicine is wrongor divided in a way that justifies opting out.
Clinicians then spend precious time rebuilding context: how scientific disagreement works, how weak studies can produce
misleading claims, and how public-health recommendations rely on cumulative evidence, not isolated signals.

The researcher experience: “Your work becomes a slogan.”

Scientists working in immunology often report a frustrating disconnect: they publish cautious languagelimitations,
confounders, uncertaintyand then see a simplified version ricochet online as a definitive claim. When research touches
vaccines, the distortion can be dramatic. A hypothesis becomes a verdict. An animal model becomes a human outcome. A
correlation becomes a conspiracy.

For researchers, controversies like the Shoenfeld debate can feel like watching science get turned into a costume:
people wear the aesthetics of evidence while ignoring the discipline of evidence. That’s one reason some scientists push
institutions to think harder about what honors signal to the public.

The journal/editor experience: “Withdrawing a paper isn’t a victoryit’s damage control.”

Editors describe withdrawals and retractions as among the least glamorous parts of the job. It’s not “cancel culture”;
it’s quality control under pressure. And when a withdrawn claim is later republished elsewhere, editors can feel the
ground shift beneath the system: the same conclusion re-enters public discourse with a fresh coat of legitimacy.

From that perspective, institutional prestige matters because it can shape which outlets take a submission seriously,
which conferences extend invitations, and which media producers treat a guest as authoritative. A title can open doors
including doors that lead straight into misinformation pipelines.

The public-health communicator experience: “We’re competing with certainty.”

Public-health messaging is often careful because reality is complicated. But careful messaging can sound weak next to a
confident viral claim. Communicators frequently talk about the “asymmetry of persuasion”: it takes a few seconds to say
“this ingredient is toxic,” and far longer to explain dose, exposure, immune response, epidemiology, and risk-benefit.

When a respected scientist promotes contested frameworksor when their work is interpreted as supporting broad vaccine
harmcommunicators inherit the cleanup. They must acknowledge uncertainty where it exists, defend what is well supported,
and avoid shaming people who are scared. That’s emotionally labor-intensive work, especially when trust has been
eroded.

The patient experience: “I just want someone to take my symptoms seriously.”

It’s also important to recognize why broad syndromes gain traction. People living with chronic fatigue, pain, and
neurological symptoms often bounce between providers without answers. When a framework like ASIA offers a single label
and a causal story, it can feel like relieffinally, an explanation.

The tragedy is that a satisfying explanation is not always a correct one. When institutions debate controversial figures,
the best outcome is not “winning the argument.” It’s improving the system so patients get rigorous evaluation, compassionate
care, and honest uncertaintywithout being funneled into narratives that overpromise causation.

What these experiences suggest for institutions

If scientific organizations want to protect public trust, they can’t rely on prestige alone. They need clear public
standards: commitments to methodological rigor, corrections when claims are wrong, and proactive communication about what
honors do (and do not) endorse. In a world where credentials travel faster than context, context is part of the credential.

Conclusion

The election of Yehuda Shoenfeld to the Israel Academy of Sciences and Humanities became controversial because it sits at
the intersection of real scientific achievement and real public-health risk. Autoimmunity research is
vital. Vaccine safety work is vital. But when contested frameworks and flawed research become fuel for anti-vaccine
narratives, institutions face a modern responsibility: not only to honor science, but to guard how scientific authority
is interpreted and used.

You can respect a scientist’s contributions while still demanding rigorous evidence for controversial claims. And you
can recognize an academy’s autonomy while still insisting that prestige comes with public consequences. In 2026, that’s
not “politicizing science.” It’s acknowledging that science already lives in the public squarewhether it wants to or not.